BIOSANTE PHARMACEUTICALS INC Form 8-K May 03, 2010

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2010 BIOSANTE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware 001-31812 58-2301143

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

111 Barclay Boulevard Lincolnshire, Illinois

60069

(Address of principal executive offices)

(Zip Code)

Registrant s telephone number, including area code: (847) 478-0500

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### Section 8 Other Events Item 8.01. Other Events.

BioSante Pharmaceuticals, Inc. is filing this current report on Form 8-K to file as an exhibit the license agreement dated December 3, 2008 between BioSante Pharmaceuticals, Inc. and Azur Pharma International II, Limited, as amended.

**Section 9 Financial Statements and Exhibits Item 9.01. Financial Statements and Exhibits.** (d) *Exhibits*.

#### Exhibit

No. Description
 10.1 License Agreement dated December 3, 2008 between BioSante Pharmaceuticals, Inc. and Azur Pharma International II, Limited\*
 10.2 Amendment No. 1 to License Agreement and Asset Purchase Agreement dated December 7, 2009 between

BioSante Pharmaceuticals, Inc. and Azur Pharma International II, Limited\*

<sup>\*</sup> Confidential treatment has been requested with respect to designated portions of this document. Such portions have been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### BIOSANTE PHARMACEUTICALS, INC.

By: /s/ Phillip B. Donenberg
Phillip B. Donenberg
Chief Financial Officer, Treasurer and
Secretary

Dated: May 3, 2010

## BIOSANTE PHARMACEUTICALS, INC. FORM 8-K Exhibit Index

Exhibit No.	Description	<b>Method of Filing</b>
10.1	License Agreement dated December 3, 2008 between BioSante Pharmaceuticals,	Filed herewith
	Inc. and Azur Pharma International II, Limited (*)	
10.2	Amendment No. 1 to License Agreement and Asset Purchase Agreement dated	Filed herewith
	December 7, 2009 between BioSante Pharmaceuticals, Inc. and Azur Pharma	
	International II, Limited (*)	

<sup>\*</sup> Confidential treatment has been requested with respect to designated portions of this document. Such portions have been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.